Status: Prior Investments

Tourmaline Bio

Clinical-stage company developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases.

Completed reverse merger in 2023

Escient Pharmaceuticals

Clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders.

Acquired by Incyte in 2024

Antios Therapeutics

Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).

Caribou Biosciences

Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Completed IPO in 2021

Arch Oncology

Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.

Immunocore

Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Completed IPO in 2021

Sentynl Therapeutics

Commercial-stage specialty pharmaceutical company focused on pain management and adjacent specialty therapeutics areas.

Acquired by Zydus in 2017

Amber Ophthalmics

Clinical-stage ophthalmic company focused on novel therapeutics to address unmet medical needs, providing for the restoration, preservation, and improvement of patient vision and quality of life.

Acquired by a strategic in 2024

Eyevance Pharmaceuticals

Commercial-stage specialty ophthalmic company focused on innovative and impactful branded prescription products targeting the anterior segment of the eye.

Acquired by Santen in 2020